A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†-Reference-Cited by-同舟云学术

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†

Published:2018-10-10 Issue:4 Volume:60 Page:912-919
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Reiman Tony¹,Savage Kerry J.²,Crump Michael³,Cheung Matthew C.⁴,MacDonald David⁵,Buckstein Rena⁴,Couban Stephen⁵,Piliotis Eugenia⁴,Imrie Kevin⁶,Spaner David⁴,Shivakumar Sudeep⁵,Kuruvilla John³,Villa Diego⁷^ORCID,Shepherd Lois E.⁷,Skamene Tanya⁷,Winch Chad⁷,Chen Bingshu E.⁷,Hay Annette E.⁷

Affiliation:

1. Department of oncology, Saint John Regional Hospital, Dalhousie University, and University of New Brunswick, Saint John, Canada;

2. BC Cancer Agency, Vancouver, Canada;

3. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada;

4. Division of Hematology, Sunnybrook Health Services Centre, Toronto, Canada;

5. Department of Hematology, QEII Health Sciences Centre, Halifax, Canada;

6. Department of Hematology, Sunnybrook Health Services Centre, Toronto, Canada;

7. Canadian Cancer Trials Group, Cancer Research Institute, Queen's University, Kingston, Canada

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1515937

Reference39 articles.

1. International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

2. Towards understanding the peripheral T-cell lymphomas

3. T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment

4. Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma;Journal of Hematology & Oncology;2024-06-01

2. HDAC inhibitors: Promising agents for leukemia treatment;Biochemical and Biophysical Research Communications;2023-11

3. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL);Clinical Epigenetics;2023-08-02

4. Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin;Biomedicine & Pharmacotherapy;2023-08

5. Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: a systematic review and meta-analysis on prospective clinical trials;Frontiers in Oncology;2023-06-13